Home / Market News / $ALNY
fiscal.ai Corporate Catalyst Impact 75/100 ● positive

Alnylam Collaborator Regeneron Reports Positive First-in-Human Results for CIDEBsiRNA

Nov 10, 2026, 7:05 PM UTC · Primary ticker $ALNY

Alnylam's collaborator, Regeneron, announced positive first-in-human clinical trial results for CIDEBsiRNA, an RNAi therapeutic for MASLD. The drug rapidly normalized liver fat and improved liver injury markers, indicating significant potential for this treatment and validating Alnylam's RNAi platform.

Alnylam's collaborator, Regeneron, reported promising first-in-human results for CIDEBsiRNA, an RNAi therapeutic targeting MASLD. The study showed a single dose rapidly normalized liver fat and improved liver injury markers, which is a significant positive for both companies. This validates Alnylam's RNAi technology platform and strengthens its pipeline, while for Regeneron, it represents a potential new blockbuster drug in a large market. Short-term, this could lead to increased investor confidence and a boost in stock prices for both ALNY and REGN. Long-term, successful development of CIDEBsiRNA could unlock substantial revenue streams and further solidify Alnylam's position as a leader in RNAi therapeutics, and Regeneron's in metabolic diseases. The key opportunity for traders is the potential for continued positive news as the drug progresses through further clinical trials.

$ALNY positive Positive clinical trial results for partnered drug
$REGN positive Positive clinical trial results for developed drug
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.